{"gene":"TFAP2A","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1991,"finding":"TFAP2A mRNA is expressed in neural crest cells and their major derivatives (cranial and spinal sensory ganglia, facial mesenchyme) during mouse embryogenesis between E8.5 and E12.5, as determined by RNA in situ hybridization, consistent with a transcriptional regulatory role in peripheral nervous system and craniofacial morphogenesis.","method":"RNA in situ hybridization, RNase protection assay","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by in situ hybridization replicated across multiple time points, but functional consequence not yet established in this paper","pmids":["1989904"],"is_preprint":false},{"year":1996,"finding":"Targeted disruption of the mouse AP-2 (Tcfap2a) gene causes perinatal lethality with cranio-abdominoschisis, severe craniofacial dysmorphogenesis, and failure of cranial neural tube closure coinciding with increased apoptosis in the midbrain and first branchial arch; loss of AP-2 does not eliminate expression of twist or Pax-3.","method":"Targeted gene disruption (knockout mouse), histology, in situ hybridization","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with defined lethal phenotype, replicated independently in two concurrent papers (PMID 8622765 and related work), multiple morphological readouts","pmids":["8622765"],"is_preprint":false},{"year":1996,"finding":"AP-2alpha and AP-2gamma (but not AP-2beta) bind to and activate the c-erbB-2 (HER2) promoter as homo- or heterodimers, with AP-2alpha and AP-2gamma being 3–4 times more transcriptionally active than AP-2beta at this promoter.","method":"DNA binding assays, reporter gene (transient transfection), protein purification/sequencing","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus affinity purification identifying specific family members; single lab but multiple orthogonal methods","pmids":["8895516"],"is_preprint":false},{"year":1998,"finding":"AP-2alpha DNA-binding activity is reversibly inhibited by oxidation of conserved cysteine residues (by diamide or hydrogen peroxide) and restored by reducing agents including thioredoxin, as shown by in vitro DNA-binding and non-reducing immunoblot assays with recombinant human AP-2.","method":"In vitro DNA-binding assay (EMSA), non-reducing SDS-PAGE/immunoblot, recombinant protein","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with recombinant protein, single lab, single study","pmids":["9712692"],"is_preprint":false},{"year":1998,"finding":"AP-2 exerts a non-cell-autonomous influence on eye formation and limb patterning (causing major limb duplications) in addition to its cell-autonomous requirements in the neural tube and body wall, as revealed by chimeric mice composed of wild-type and AP-2-null cells.","method":"Chimeric mouse analysis (wild-type/AP-2-null)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic chimera approach revealing tissue-level autonomy, single lab but clear functional readouts","pmids":["9811866"],"is_preprint":false},{"year":1995,"finding":"AP-2 directly trans-activates the dopamine beta-hydroxylase (DBH) gene promoter by binding to an AP-2 site at -136 to -115; mutation of this site reduces basal reporter expression 7-fold, and co-transfection of AP-2 expression vector stimulates reporter expression 6-fold.","method":"DNase footprinting, reporter gene assay (co-transfection), site-directed mutagenesis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro footprinting plus mutagenesis plus reporter assay in cell culture, single lab","pmids":["7616204"],"is_preprint":false},{"year":1999,"finding":"AP-2 transcription factors (all three members) repress Mn-SOD promoter activity in a DNA-binding-dependent manner; a dominant-negative AP-2 (AP-2B) that cannot bind DNA relieves this repression; AP-2alpha and AP-2gamma are more active repressors than AP-2beta.","method":"Reporter gene co-transfection assay, dominant-negative AP-2 expression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter plus dominant-negative rescue, single lab, two orthogonal approaches","pmids":["11278550"],"is_preprint":false},{"year":2001,"finding":"CITED2 directly interacts with and co-activates all TFAP2 isoforms; TFAP2 transactivation is defective in Cited2-/- embryonic fibroblasts and rescued by ectopic CITED2 expression, establishing CITED2 as a TFAP2 co-activator required for normal neural crest, neural tube, and cardiac development.","method":"Co-immunoprecipitation, reporter gene assay in Cited2-/- fibroblasts, rescue by ectopic expression, knockout mouse phenotype","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction shown by Co-IP, functional rescue in knockout fibroblasts, corroborated by in vivo phenotypic overlap with Tfap2 mutants","pmids":["11694877"],"is_preprint":false},{"year":2002,"finding":"TFAP2A interacts with the SUMO-conjugating enzyme UBC9 (identified by two-hybrid screen) via its C-terminal DNA-binding/dimerization domain; endogenous AP-2 is SUMOylated in mammalian cells at conserved lysine 10, and SUMOylation decreases TFAP2A transcriptional activation potential.","method":"Yeast two-hybrid screen, in vivo SUMOylation assay, site-directed mutagenesis (K10), reporter gene (transient transfection)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — identified writer (UBC9/SUMO pathway), mapped modification site by mutagenesis, showed functional consequence on transactivation; single lab but multiple orthogonal methods","pmids":["12072434"],"is_preprint":false},{"year":2002,"finding":"XAP-2 (Xenopus AP-2alpha) is a critical regulator of epidermal determination; ectopic XAP-2 expression restores epidermal gene transcription in neuralized ectoderm, while loss-of-function via antisense oligonucleotides or antimorphic derivatives causes loss of epidermal and gain of neural gene expression, and results in gastrulation failure.","method":"Ectopic overexpression in Xenopus embryo, antisense oligonucleotide knockdown, dominant-negative (antimorphic) expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with specific molecular readouts in Xenopus; single lab","pmids":["11969261"],"is_preprint":false},{"year":2004,"finding":"In zebrafish, tfap2a (mont blanc/mob) is required for the normal developmental program and survival of neural crest cells in pharyngeal arches 2–7 and trunk; the mutation disrupts the DNA-binding/dimerization domain, abolishes expression of sox9a, wnt5a, dlx2, hoxa2/b2 in craniofacial primordia, and causes apoptosis of a subset of neural crest cells without affecting initial specification or migration.","method":"Positional candidate cloning, splice-site mutation characterization, in situ hybridization (neural crest markers), TUNEL/Acridine Orange apoptosis assay, live cell fate tracing","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function allele with defined molecular lesion, multiple downstream target genes assayed, cell fate tracing, replicated with orthogonal apoptosis assays","pmids":["14985255"],"is_preprint":false},{"year":2004,"finding":"In zebrafish tfap2a (lockjaw) mutants, defects in hyoid arch cartilage correlate with loss of Hox group 2 gene expression (suggesting homeotic transformation to mandibular fate), and early melanophores fail to develop partly through loss of kit function affecting migration, revealing independent roles for tfap2a in pigment cell specification and Hox-mediated skeletal patterning.","method":"Zebrafish mutant analysis, in situ hybridization (Hox genes, pigment markers), genetic interaction with kit","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple molecular marker readouts and pathway placement, single lab","pmids":["14699580"],"is_preprint":false},{"year":2006,"finding":"Conditional knockout of AP-2alpha in mouse epidermis causes elevated EGFR expression in differentiating layers, hyperproliferation upon EGF stimulation, and excessive PI3K/Akt activity; chromatin immunoprecipitation and promoter assays identify EGFR as a direct transcriptional target of AP-2alpha repression.","method":"Conditional knockout mouse (cre-lox), chromatin immunoprecipitation (ChIP), promoter reporter assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — conditional KO with defined phenotype, ChIP demonstrating direct promoter occupancy, reporter assay confirming repression; single lab but multiple orthogonal methods","pmids":["16449191"],"is_preprint":false},{"year":2006,"finding":"In zebrafish, tfap2a and tfap2c act redundantly in neural crest induction; simultaneous inhibition of both genes utterly prevents neural crest induction, and cell transplant experiments indicate this role is cell-autonomous.","method":"Antisense morpholino knockdown, cell transplantation assay, in situ hybridization","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double knockdown with cell-autonomous transplant evidence, single lab","pmids":["17258188"],"is_preprint":false},{"year":2008,"finding":"TFAP2 transcription factors are identified as repressors of the TBX20 gene: functional TFAP2 binding sites were found within the human TBX20 core promoter, and TFAP2 repressed TBX20 expression in vitro (reporter assay) and in vivo (ChIP and cardiac biopsy analysis showing decreased TFAP2C in TOF patients).","method":"Reporter gene assay, ChIP, cardiac biopsy expression analysis","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus ChIP plus in vivo correlation, single lab","pmids":["18275040"],"is_preprint":false},{"year":2010,"finding":"AP-2alpha (TFAP2A) directly binds to two regions of the CDKN1A (p21cip) promoter—a proximal AP-2 site and an upstream region near the p53 binding site—as shown by ChIP; mutation of the proximal AP-2 site reduces p53-independent p21 expression, and this interaction pattern changes temporally post-induction.","method":"ChIP, site-directed mutagenesis of promoter, reporter gene assay","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — ChIP with mutagenesis and reporter assay, single lab, multiple approaches","pmids":["21084835"],"is_preprint":false},{"year":2010,"finding":"In AP-2alpha knockout mice, loss of AP-2alpha in multiple craniofacial tissues disrupts optic cup patterning and optic stalk morphogenesis; ectopic neural retina replaces RPE, coloboma and optic stalk extension failure occur, associated with increased Sonic Hedgehog signaling and expanded PAX2-positive optic stalk-like tissue in the optic cup.","method":"AP-2alpha knockout mouse, in situ hybridization, immunofluorescence, Shh pathway analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO with defined molecular pathway (Shh) disturbance; single lab, multiple molecular markers","pmids":["20150232"],"is_preprint":false},{"year":2010,"finding":"TFAP2 and SRF bind directly to FXN (frataxin) promoter sequences as shown by ChIP and EMSA; mutagenesis of these binding sites reduces FXN promoter activity; overexpression of TFAP2 increases frataxin mRNA and protein levels in HEK293 and SH-SY5Y cells and in Friedreich ataxia patient lymphoblasts.","method":"ChIP, EMSA, luciferase reporter mutagenesis, overexpression in cell lines and patient cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct binding by ChIP+EMSA plus mutagenesis plus functional rescue, single lab","pmids":["20808827"],"is_preprint":false},{"year":2010,"finding":"CREB suppresses AP-2alpha (TFAP2A) expression in metastatic melanoma via a dual mechanism: direct binding of CREB to the AP-2alpha promoter and CREB-induced upregulation of E2F-1, both of which repress AP-2alpha; silencing CREB restores AP-2alpha expression and upregulates p21Waf1 and downregulates MCAM/MUC18.","method":"shRNA silencing of CREB, PKA inhibitor treatment, promoter ChIP, rescue expression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual mechanisms demonstrated by ChIP and rescue experiments; single lab","pmids":["20805990"],"is_preprint":false},{"year":2012,"finding":"Tfap2a directly activates sox10 expression in neural crest cells; zebrafish rescue experiments (depleting endogenous tfap2a and replacing with various Tfap2 orthologs) show this regulatory interaction arose with the emergence of the neural crest, as AP2 and SoxE are not co-expressed in amphioxus and neural crest enhancers are absent proximal to amphioxus soxE.","method":"Zebrafish rescue with ortholog series, in situ hybridization, enhancer analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct target relationship established by rescue genetics and comparative enhancer analysis; single lab","pmids":["22241841"],"is_preprint":false},{"year":2013,"finding":"TFAP2A mutations causing Branchio-Oculo-Facial Syndrome (BOFS) localize predominantly to the DNA-binding domain; functional analysis shows that individual mutations reduce DNA binding to different extents, yet all show significantly reduced transcriptional activity; several mutants show altered nuclear:cytoplasmic distribution and can exert dominant-negative activity on wild-type AP-2alpha.","method":"Reporter gene assay (transcriptional activity), EMSA (DNA binding), subcellular localization (immunofluorescence), dominant-negative assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple BOFS mutants analyzed by three orthogonal functional methods (DNA binding, transactivation, localization) in a single systematic study","pmids":["23578821"],"is_preprint":false},{"year":2014,"finding":"AP-2alpha recruits the histone H3K9 methyltransferases Suv39h1 and G9a to the C/EBPalpha promoter; G9a deposits H3K9me2 (substrate for Suv39h1) and Suv39h1 deposits H3K9me3, together mediating AP-2alpha-dependent transcriptional repression of C/EBPalpha to inhibit adipogenesis.","method":"Co-immunoprecipitation (AP-2alpha with Suv39h1 and G9a), ChIP (H3K9me2/me3 at C/EBPalpha promoter), knockdown/overexpression in 3T3-L1 preadipocytes","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP plus ChIP for histone marks plus functional rescue; mechanistic pathway reconstituted with multiple orthogonal methods in one study","pmids":["24732798"],"is_preprint":false},{"year":2015,"finding":"Tfap2a and Tfap2b act downstream of Ptf1a to promote amacrine cell differentiation in the mouse retina; RNA-seq shows Tfap2a/b expression is dramatically reduced in Ptf1a-null retinas; overexpression promotes glycinergic/GABAergic amacrine cells at the expense of photoreceptors, and simultaneous knockdown has the opposite effect, placing Tfap2a/b in the Foxn4/RORβ1–Ptf1a–Tfap2a/b cascade.","method":"RNA-seq, immunolabeling, overexpression, simultaneous knockdown (siRNA/shRNA), retinal explant analysis","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by gain- and loss-of-function with molecular marker readouts; single lab","pmids":["25966682"],"is_preprint":false},{"year":2015,"finding":"In zebrafish inner ear, Tfap2a coordinates BMP7a, Fgf, and Notch signaling to regulate statoacoustic ganglion (SAG) neurogenesis; Tfap2a acts non-cell-autonomously to activate Bmp7a expression, which in turn inhibits both Fgf and Notch; blocking Bmp signaling reverses the effects of Tfap2a overexpression.","method":"Loss-of-function/gain-of-function in zebrafish, genetic mosaic analysis, pharmacological inhibitors, in situ hybridization","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement by epistasis and genetic mosaic, multiple signaling readouts; single lab","pmids":["25781991"],"is_preprint":false},{"year":2017,"finding":"TFAP2A paralogs (TFAP2A and TFAP2B) in mouse neural crest are required for induction of the melanocyte lineage; Wnt1-Cre deletion of both Tfap2a and Tfap2b almost completely eliminates melanocytes but retains sensory ganglia; ChIP-seq shows TFAP2A co-occupies regulatory elements with MITF at pigmentation genes (e.g., TRPM1 promoter), and deletion of TFAP2A binding sites abolishes TRPM1 promoter activity.","method":"Conditional double knockout (Wnt1-Cre), ChIP-seq, luciferase reporter with site deletion, zebrafish genetic interaction","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP-seq plus mutagenesis plus conditional double KO plus genetic interaction; multiple labs and organisms","pmids":["28249010"],"is_preprint":false},{"year":2017,"finding":"TFAP2A functions as a repressor of ZEB2 by directly binding the ZEB2 promoter, as demonstrated by EMSA and ChIP in NMuMG cells undergoing EMT; TFAP2A is a component of the core EMT gene regulatory network.","method":"EMSA, ChIP, overexpression and endogenous knockdown analysis in NMuMG EMT model","journal":"Biology direct","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct binding demonstrated by EMSA and ChIP with functional consequence on ZEB2; single lab","pmids":["28412966"],"is_preprint":false},{"year":2018,"finding":"TFAP2 family members mediate Wnt3a-induced lipid droplet biogenesis; TFAP2 knockdown prevents Wnt-induced lipid droplet formation, identifying TFAP2 transcription factors as regulators of lipid droplet biogenesis downstream of Wnt signaling and independent of canonical TCF/LEF factors.","method":"RNAi knockdown, lipid droplet quantification (imaging), reporter assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific lipid droplet readout and pathway placement; single lab","pmids":["30256193"],"is_preprint":false},{"year":2019,"finding":"TFAP2A acts as a pioneer factor that activates distinct sets of genomic regions at different stages of neural crest development; TFAP2A/C heterodimers activate neural plate border induction programs during gastrula stages, while TFAP2A/B heterodimers reorganize the epigenomic landscape during neurulation to promote neural crest specification, representing a stage-specific molecular switch.","method":"ChIP-seq (genomic occupancy), ATAC-seq (chromatin accessibility), in vivo Xenopus model, dimerization partner analysis","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — pioneer factor activity shown by ChIP-seq and chromatin accessibility assays with partner-specific functional analysis; single lab but multiple orthogonal genomic methods","pmids":["31848212"],"is_preprint":false},{"year":2019,"finding":"In the zebrafish pronephros, tfap2a acts downstream of irx3b (a distal lineage transcription factor) to activate a gene regulatory circuit comprising tfap2b, irx1a, and solute transporter genes (slc12a1, kcnj1a.1, stc1) that dictate distal nephron segment identity; kctd15a/b repress Tfap2a activity, and tfap2a reciprocally promotes kctd15a/b transcription, forming an autoregulatory feedback circuit.","method":"Forward genetic screen (zebrafish), morpholino knockdown, overexpression, in situ hybridization, epistasis analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by genetic screen and multiple rescue/knockdown combinations; single lab","pmids":["31160420","33028614"],"is_preprint":false},{"year":2019,"finding":"AP-2alpha directly binds the Nanog gene regulatory region (shown by EMSA and luciferase reporter assay) and reduces Nanog, Sox2, and CD133 expression; AP-2alpha also indirectly downregulates Nanog by inhibiting the IL6/JAK2/STAT3 signaling pathway, thereby reducing MGMT and PD-L1 expression and suppressing glioma stem cell self-renewal.","method":"Luciferase reporter assay, EMSA, Western blot, sphere-formation assay, xenograft model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA binding by EMSA plus reporter assay plus pathway inhibition phenotype; single lab","pmids":["31534499"],"is_preprint":false},{"year":2019,"finding":"Over-expression of the Tfap2a-Irf6-Grhl3 genetic pathway is conserved in neurulation: over-expression of Irf6 causes exencephaly by suppressing Tfap2a and Grhl3 expression, while loss of Irf6 reduces Tfap2a and Grhl3 in tail tissues; Tfap2a and Grhl3 are thus epistatic to Irf6 in this pathway controlling both neural tube closure and orofacial development.","method":"Mouse overexpression and loss-of-function models, in situ hybridization, sequencing of human neural tube defect samples","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in mouse established by gain- and loss-of-function with molecular marker readouts; single lab","pmids":["30689861"],"is_preprint":false},{"year":2020,"finding":"In melanoma, AP-2alpha (TFAP2A) drives metastasis by transcriptionally activating EZH2 and other E2F pathway genes; BioID screen reveals AP-2alpha interacts with members of the NuRD complex; loss of AP-2alpha removes activating chromatin marks from EZH2 and E2F target gene promoters through NuRD-mediated repression; tazemetostat (EZH2 inhibitor) efficacy is AP-2alpha-dependent.","method":"BioID proximity labeling screen, ChIP (histone marks), CRISPR/shRNA knockout, drug sensitivity assay, single-cell RNA-seq","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BioID identifies NuRD complex interaction, ChIP shows chromatin mark changes; single lab, multiple orthogonal methods","pmids":["34210752"],"is_preprint":false},{"year":2020,"finding":"AP-2alpha (TFAP2A) binds directly to the CD274 (PD-L1) promoter and inhibits its transcriptional activity; AP-2alpha also enhances endocytosis and degradation of PD-L1 protein; AP-2alpha gene is epigenetically silenced in glioma by an EZH2/H3K27Me3/DNMT1 complex-mediated methylation mechanism.","method":"Reporter gene assay, ChIP (AP-2alpha on CD274 promoter), flow cytometry (PD-L1 surface levels), endocytosis assay, bisulfite sequencing/ChIP for H3K27me3/DNMT1","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by ChIP plus reporter plus endocytosis assay; single lab, multiple mechanisms tested","pmids":["37330579"],"is_preprint":false},{"year":2021,"finding":"AP-2alpha (TFAP2A) drives cell cycle S-phase progression in colon cancer through transcriptional activation of TGM2, which in turn activates AKT phosphorylation; CRISPR/shRNA knockout of TFAP2A delays S-phase to G2-M progression and decreases pAKT, mediated through TGM2; loss of AP-2alpha also induces resistance to PI3K inhibitor buparlisib.","method":"CRISPR-Cas9 and shRNA knockout, ChIP-seq, RNA-seq, FACS cell cycle analysis, Premo FUCCI cell cycle reporter, AKT phosphorylation assay, xenograft","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP-seq identifying direct target TGM2, functional cell cycle and signaling readouts with CRISPR KO and multiple orthogonal methods in one systematic study","pmids":["33753551"],"is_preprint":false},{"year":2022,"finding":"TFAP2 paralogs (TFAP2A and TFAP2C) are required for MITF binding and chromatin accessibility at pigmentation and proliferation gene enhancers in melanoma cells; TFAP2-KO (CRISPR) cells show reduced H3K27Ac and MITF binding at co-occupied enhancers, decreased proliferation, and increased cell adhesion; TFAP2 and MITF co-operatively activate a subset of enhancers with TFAP2 acting upstream to facilitate MITF access.","method":"CRISPR knockout, ATAC-seq, ChIP-seq (TFAP2A, MITF, H3K27Ac, H3K27Me3), RNA-seq","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple genome-wide orthogonal assays in CRISPR KO cells; rigorous integrated analysis; single lab but comprehensive multi-omic approach","pmids":["35580127"],"is_preprint":false},{"year":2011,"finding":"Alternative TFAP2A isoforms differ in transcriptional activity: isoforms 1a, 1b, and 1c share a transactivation mechanism recruiting CITED2/4 adaptor proteins and the p300/CBP co-activators, but isoform 1b and 1c are stronger activators of the ERBB2 promoter; only isoform 1a can repress transcription, and this repressor activity requires an intact sumoylation motif in its unique N-terminus.","method":"Reporter gene assay, isoform-specific antibody characterization, isoform expression in breast cell lines and tumors","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays with multiple isoforms plus sumoylation motif requirement established; single lab","pmids":["21375726"],"is_preprint":false},{"year":2024,"finding":"SRC-mediated tyrosine phosphorylation of YAP1 facilitates YAP1 interaction with TFAP2A, forming a YAP1/TEAD-TFAP2A (YTT) complex that co-occupies regulatory regions of trastuzumab resistance genes (EGFR, HER2, H19, CTGF) and drives their transcription; disruption of the YTT complex or SRC inhibition sensitizes HER2+ breast cancer cells to trastuzumab.","method":"Co-IP (YAP1-TFAP2A interaction), ChIP-seq (YTT complex occupancy), reporter gene assay, SRC inhibition, drug sensitivity assay in vitro and in vivo","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP-seq plus functional drug sensitivity; single lab, multiple orthogonal methods","pmids":["38219531"],"is_preprint":false},{"year":2020,"finding":"Lactate from CRC cells induces nuclear translocation of Ap-2alpha in tumor-associated macrophages (TAMs), where it functions as a transcriptional activator of Elk-1 by binding the conserved element GCCTGC at -1396/-1391 in the mouse Elk-1 promoter; Elk-1 then binds the Sirpα promoter to upregulate Sirpα and suppress TAM phagocytosis.","method":"Reporter gene assay, EMSA/ChIP (Ap-2alpha binding to Elk-1 promoter), macrophage-specific knockout mouse, nuclear translocation assay","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA binding by EMSA and reporter assay, macrophage-specific KO with phagocytosis readout; single lab","pmids":["32296015"],"is_preprint":false}],"current_model":"TFAP2A (AP-2alpha) is a sequence-specific transcription factor that functions as both a transcriptional activator and repressor, forming homo- and heterodimers with paralogous TFAP2 family members via its C-terminal helix-span-helix dimerization domain; it acts as a pioneer factor to remodel chromatin at neural crest and melanocyte enhancers (facilitating MITF binding), recruits co-activators CITED2/p300/CBP to activate targets (e.g., DBH, frataxin, ERBB2, CDKN1A) and co-repressors Suv39h1/G9a to deposit H3K9me3 and silence genes (e.g., C/EBPalpha, EGFR, ZEB2, Mn-SOD); its DNA-binding activity is regulated by redox state (cysteine oxidation) and by SUMOylation at lysine 10 (reducing transactivation); TFAP2A is epigenetically silenced in melanoma by CREB/E2F-1-mediated promoter repression and by DNMT1/EZH2-driven CpG methylation; and it controls cell cycle S-phase progression through TGM2-mediated AKT activation, melanocyte lineage induction, neural crest survival and differentiation, and multiple organ morphogenesis (craniofacial, renal, ocular)."},"narrative":{"mechanistic_narrative":"TFAP2A (AP-2alpha) is a sequence-specific transcription factor that orchestrates neural crest development, craniofacial and organ morphogenesis, and lineage specification, with both activator and repressor functions [PMID:8622765, PMID:14985255, PMID:28249010]. It is expressed in neural crest cells and their derivatives during embryogenesis [PMID:1989904], and its loss causes failure of cranial neural tube closure, craniofacial dysmorphogenesis, and increased neural crest apoptosis in mouse and zebrafish [PMID:8622765, PMID:14985255]. Mechanistically, TFAP2A acts as a pioneer factor that remodels chromatin in a partner-specific manner: TFAP2A/C heterodimers drive neural plate border induction while TFAP2A/B heterodimers reorganize the epigenome for neural crest specification [PMID:31848212], and in melanocytes it (with TFAP2C) opens enhancers to facilitate MITF binding and co-operatively activate pigmentation genes such as TRPM1 [PMID:28249010, PMID:35580127]. As an activator it binds and trans-activates target promoters including DBH, FXN (frataxin), and ERBB2, recruiting the CITED2 adaptor and p300/CBP co-activators [PMID:7616204, PMID:11694877, PMID:20808827, PMID:21375726]; as a repressor it recruits the H3K9 methyltransferases Suv39h1 and G9a to deposit H3K9me2/me3 and silence targets such as C/EBPalpha, and directly represses EGFR, ZEB2, and Mn-SOD [PMID:24732798, PMID:16449191, PMID:28412966, PMID:11278550]. Its DNA-binding activity is redox-regulated through oxidation of conserved cysteines [PMID:9712692], and SUMOylation at lysine 10 via UBC9 reduces its transactivation potential [PMID:12072434]. In cancer, TFAP2A controls cell cycle S-phase progression through transcriptional activation of TGM2 and downstream AKT signaling [PMID:33753551], is epigenetically silenced in melanoma and glioma by CREB/E2F-1 and EZH2/DNMT1-mediated mechanisms [PMID:20805990, PMID:37330579], and partners with NuRD and YAP1/TEAD complexes to regulate target gene chromatin states [PMID:34210752, PMID:38219531]. Human TFAP2A mutations, predominantly in the DNA-binding domain, cause Branchio-Oculo-Facial Syndrome, reducing transactivation and conferring dominant-negative activity [PMID:23578821].","teleology":[{"year":1991,"claim":"Established where TFAP2A is deployed in the embryo, anchoring the hypothesis that it regulates neural crest and craniofacial programs.","evidence":"RNA in situ hybridization and RNase protection across mouse embryonic stages E8.5–E12.5","pmids":["1989904"],"confidence":"Medium","gaps":["Expression alone does not establish function","No direct target genes identified"]},{"year":1996,"claim":"Demonstrated that TFAP2A is essential for neural tube closure and craniofacial development, converting an expression correlation into a causal developmental requirement.","evidence":"Targeted gene disruption in mouse with histology and in situ hybridization","pmids":["8622765"],"confidence":"High","gaps":["Molecular targets driving the phenotype not defined","Cell-autonomy not resolved"]},{"year":1995,"claim":"Identified the first direct activation target and DNA-binding mechanism, showing TFAP2A trans-activates promoters through defined AP-2 sites.","evidence":"DNase footprinting, site-directed mutagenesis, and reporter assays on the DBH promoter; reporter/affinity work on c-erbB-2","pmids":["7616204","8895516"],"confidence":"Medium","gaps":["Co-activator requirements not yet defined","In vivo relevance of these targets untested"]},{"year":1998,"claim":"Revealed that TFAP2A activity is post-translationally controlled, with DNA binding reversibly inhibited by cysteine oxidation, linking its function to cellular redox state.","evidence":"In vitro EMSA and non-reducing immunoblot with recombinant protein and oxidizing/reducing agents","pmids":["9712692"],"confidence":"Medium","gaps":["In vitro reconstitution only","Physiological relevance of redox regulation in vivo unestablished"]},{"year":1998,"claim":"Distinguished cell-autonomous from non-cell-autonomous requirements, showing TFAP2A influences eye and limb patterning at the tissue level beyond its own lineage.","evidence":"Chimeric mouse analysis combining wild-type and AP-2-null cells","pmids":["9811866"],"confidence":"Medium","gaps":["Signaling intermediaries mediating non-autonomous effects unknown"]},{"year":2001,"claim":"Identified CITED2 as a required co-activator, providing the first molecular partner explaining how TFAP2A activates transcription during development.","evidence":"Co-IP, reporter rescue in Cited2-/- fibroblasts, and knockout mouse phenotype overlap","pmids":["11694877"],"confidence":"High","gaps":["Direct contact with general co-activators not mapped here","Target-specific recruitment unresolved"]},{"year":2002,"claim":"Defined SUMOylation at lysine 10 via UBC9 as a negative regulator of TFAP2A transactivation, establishing a covalent switch on its activity.","evidence":"Yeast two-hybrid, in vivo SUMOylation assay, K10 mutagenesis, reporter assays","pmids":["12072434"],"confidence":"High","gaps":["SUMO E3 ligase not identified","Genomic targets affected by SUMOylation undefined"]},{"year":2002,"claim":"Established a conserved developmental fate-decision role, with AP-2alpha required for epidermal versus neural ectoderm choice.","evidence":"Gain- and loss-of-function in Xenopus with epidermal/neural gene readouts","pmids":["11969261"],"confidence":"Medium","gaps":["Direct targets in epidermal determination not defined"]},{"year":2004,"claim":"Pinpointed the neural crest survival and craniofacial patterning role to the DNA-binding/dimerization domain and a downstream target network (sox9a, dlx2, hoxa2/b2), separating differentiation from specification and migration.","evidence":"Zebrafish positional cloning, marker in situ hybridization, apoptosis assays, and cell fate tracing in mont blanc/lockjaw mutants","pmids":["14985255","14699580"],"confidence":"High","gaps":["Which targets are direct vs indirect not fully resolved","Mechanism of cell-type-specific apoptosis unknown"]},{"year":2006,"claim":"Defined TFAP2A as a direct transcriptional repressor in differentiated tissue, restraining EGFR and downstream PI3K/Akt signaling in epidermis.","evidence":"Conditional epidermal knockout, ChIP, and promoter reporter assays","pmids":["16449191"],"confidence":"High","gaps":["Co-repressor machinery at EGFR not identified in this study"]},{"year":2010,"claim":"Expanded the direct target repertoire across activation (FXN) and repression (Mn-SOD, CDKN1A, TBX20), establishing TFAP2A as a bifunctional regulator engaging promoters context-dependently.","evidence":"ChIP, EMSA, promoter mutagenesis, reporter assays, and overexpression across cell and patient models","pmids":["20808827","11278550","21084835","18275040"],"confidence":"Medium","gaps":["Determinants of activator vs repressor mode at a given promoter unclear","Co-factors mediating each mode not defined here"]},{"year":2010,"claim":"Showed TFAP2A is epigenetically silenced in melanoma via CREB/E2F-1, linking its loss to metastatic gene programs and p21/MCAM regulation.","evidence":"shRNA silencing of CREB, PKA inhibition, promoter ChIP, and rescue in melanoma cells","pmids":["20805990"],"confidence":"Medium","gaps":["Whether CREB-driven silencing initiates or maintains melanoma progression untested"]},{"year":2012,"claim":"Established TFAP2A as a direct upstream activator of sox10 and traced the origin of this regulatory link to the evolutionary emergence of the neural crest.","evidence":"Zebrafish rescue with ortholog series, in situ hybridization, comparative enhancer analysis","pmids":["22241841"],"confidence":"Medium","gaps":["Direct enhancer contacts in vertebrates not mapped at base-pair resolution"]},{"year":2014,"claim":"Reconstituted the repressive chromatin mechanism, showing TFAP2A recruits G9a and Suv39h1 to deposit H3K9me2/me3 and silence target genes such as C/EBPalpha.","evidence":"Co-IP, ChIP for H3K9me2/me3, and knockdown/overexpression in 3T3-L1 preadipocytes","pmids":["24732798"],"confidence":"High","gaps":["Whether this complex operates at other repressed targets not tested here"]},{"year":2015,"claim":"Placed TFAP2A in defined transcriptional cascades for retinal amacrine cell fate and inner ear neurogenesis, showing it integrates signaling pathways during organ development.","evidence":"RNA-seq, epistasis, gain/loss-of-function in mouse retina and zebrafish inner ear with genetic mosaics and inhibitors","pmids":["25966682","25781991"],"confidence":"Medium","gaps":["Direct vs indirect targets within these cascades not fully resolved"]},{"year":2017,"claim":"Defined TFAP2A (with TFAP2B) as the inducer of the melanocyte lineage and demonstrated genomic co-occupancy with MITF at pigmentation enhancers.","evidence":"Conditional double knockout (Wnt1-Cre), ChIP-seq, reporter site-deletion, and zebrafish genetic interaction","pmids":["28249010"],"confidence":"High","gaps":["Mechanism of MITF facilitation not yet defined at chromatin level in this study"]},{"year":2017,"claim":"Added ZEB2 to the directly repressed targets, positioning TFAP2A within the core EMT gene regulatory network.","evidence":"EMSA and ChIP with knockdown/overexpression in the NMuMG EMT model","pmids":["28412966"],"confidence":"Medium","gaps":["Single EMT model; broader EMT relevance untested"]},{"year":2019,"claim":"Established TFAP2A as a stage-specific pioneer factor, with distinct heterodimer partners directing chromatin opening at successive neural crest developmental programs.","evidence":"ChIP-seq and ATAC-seq with partner-specific analysis in Xenopus","pmids":["31848212"],"confidence":"High","gaps":["Structural basis of partner-dependent pioneering not resolved","How the A/C-to-A/B switch is timed unknown"]},{"year":2019,"claim":"Embedded TFAP2A in tissue-specific genetic circuits, including a distal nephron autoregulatory loop with kctd15a/b and an Irf6-Tfap2a-Grhl3 neurulation/orofacial pathway.","evidence":"Forward genetic screen, knockdown/overexpression, epistasis in zebrafish pronephros and mouse models","pmids":["31160420","30689861"],"confidence":"Medium","gaps":["Direct targets within each circuit incompletely defined"]},{"year":2020,"claim":"Revealed context-dependent oncogenic roles, with TFAP2A activating EZH2/E2F programs via NuRD interaction and driving S-phase progression through TGM2/AKT.","evidence":"BioID proximity labeling, ChIP, CRISPR/shRNA knockout, ChIP-seq, FACS cell cycle and drug sensitivity assays in melanoma and colon cancer","pmids":["34210752","33753551"],"confidence":"High","gaps":["How TFAP2A switches between NuRD-repressive and activating outputs unclear","Direct vs indirect EZH2/E2F regulation not fully separated"]},{"year":2020,"claim":"Extended TFAP2A function to immune modulation and protein-level regulation, repressing CD274/PD-L1 transcription, promoting its endocytosis, and activating Elk-1 in lactate-stimulated tumor-associated macrophages.","evidence":"Reporter assays, ChIP/EMSA, flow cytometry, endocytosis assays, and macrophage-specific knockout mice","pmids":["37330579","32296015"],"confidence":"Medium","gaps":["Mechanism linking nuclear translocation signal to PD-L1 protein trafficking unclear"]},{"year":2013,"claim":"Connected TFAP2A directly to human disease, showing Branchio-Oculo-Facial Syndrome mutations cluster in the DNA-binding domain and impair transactivation while exerting dominant-negative effects.","evidence":"Systematic functional analysis of BOFS mutants by EMSA, reporter assays, and subcellular localization","pmids":["23578821"],"confidence":"High","gaps":["Genotype-phenotype correlation for variable BOFS features not resolved"]},{"year":2024,"claim":"Identified a YAP1/TEAD-TFAP2A complex assembled by SRC-mediated YAP1 phosphorylation that drives trastuzumab-resistance genes, defining a druggable TFAP2A-containing complex.","evidence":"Co-IP, ChIP-seq, reporter assays, SRC inhibition, and drug sensitivity in HER2+ breast cancer models","pmids":["38219531"],"confidence":"Medium","gaps":["Structural details of the YTT complex not resolved","Generalizability beyond HER2+ breast cancer untested"]},{"year":null,"claim":"It remains unresolved what molecular determinants dictate TFAP2A's switch between activator and repressor modes at a given locus, and how dimer-partner choice, SUMOylation, redox state, and co-factor recruitment are integrated to control its pioneer and lineage-specifying functions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking post-translational state to activator/repressor choice","Structural basis of partner-specific pioneering unknown","Hierarchy among co-activator (CITED2/p300) and co-repressor (G9a/Suv39h1/NuRD) recruitment unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,6,12,21,24,25,27,33]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,5,15,17,20,25,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20,37]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[27,34]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,12,21,24,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,10,24,27]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[21,27,34]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[15,33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,31,33]}],"complexes":["NuRD complex (interactor)","YAP1/TEAD-TFAP2A (YTT) complex"],"partners":["TFAP2C","TFAP2B","CITED2","UBC9","SUV39H1","G9A (EHMT2)","MITF","YAP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05549","full_name":"Transcription factor AP-2-alpha","aliases":["AP-2 transcription factor","Activating enhancer-binding protein 2-alpha","Activator protein 2","AP-2"],"length_aa":437,"mass_kda":48.1,"function":"Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is the only AP-2 protein required for early morphogenesis of the lens vesicle. Together with the CITED2 coactivator, stimulates the PITX2 P1 promoter transcription activation. Associates with chromatin to the PITX2 P1 promoter region","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P05549/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFAP2A","classification":"Not Classified","n_dependent_lines":68,"n_total_lines":1208,"dependency_fraction":0.056291390728476824},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EWSR1","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"RBM14","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TFAP2A","total_profiled":1310},"omim":[{"mim_id":"620426","title":"INKA BOX ACTIN REGULATOR 1; INKA1","url":"https://www.omim.org/entry/620426"},{"mim_id":"617136","title":"TFAP2A ANTISENSE RNA 2; TFAP2AAS2","url":"https://www.omim.org/entry/617136"},{"mim_id":"615240","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 15; KCTD15","url":"https://www.omim.org/entry/615240"},{"mim_id":"614447","title":"G0/G1 SWITCH GENE 2; G0S2","url":"https://www.omim.org/entry/614447"},{"mim_id":"613420","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1","url":"https://www.omim.org/entry/613420"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"breast","ntpm":30.8},{"tissue":"skin 1","ntpm":63.0}],"url":"https://www.proteinatlas.org/search/TFAP2A"},"hgnc":{"alias_symbol":["AP-2","AP-2alpha"],"prev_symbol":["TFAP2","AP2TF"]},"alphafold":{"accession":"P05549","domains":[{"cath_id":"-","chopping":"209-286","consensus_level":"high","plddt":90.7495,"start":209,"end":286},{"cath_id":"-","chopping":"295-415","consensus_level":"high","plddt":94.5044,"start":295,"end":415}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05549","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05549-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05549-F1-predicted_aligned_error_v6.png","plddt_mean":67.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFAP2A","jax_strain_url":"https://www.jax.org/strain/search?query=TFAP2A"},"sequence":{"accession":"P05549","fasta_url":"https://rest.uniprot.org/uniprotkb/P05549.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05549/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05549"}},"corpus_meta":[{"pmid":"12952941","id":"PMC_12952941","title":"Clathrin-mediated endocytosis in AP-2-depleted cells.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12952941","citation_count":564,"is_preprint":false},{"pmid":"1989904","id":"PMC_1989904","title":"Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1989904","citation_count":564,"is_preprint":false},{"pmid":"8622765","id":"PMC_8622765","title":"Transcription factor AP-2 essential for cranial closure and craniofacial development.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8622765","citation_count":523,"is_preprint":false},{"pmid":"16420676","id":"PMC_16420676","title":"The AP-2 family of transcription factors.","date":"2005","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/16420676","citation_count":361,"is_preprint":false},{"pmid":"9490719","id":"PMC_9490719","title":"AP-2/Eps15 interaction is required for receptor-mediated endocytosis.","date":"1998","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9490719","citation_count":310,"is_preprint":false},{"pmid":"11694877","id":"PMC_11694877","title":"Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11694877","citation_count":282,"is_preprint":false},{"pmid":"10459011","id":"PMC_10459011","title":"Phosphoinositide-AP-2 interactions required for targeting to plasma membrane clathrin-coated pits.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10459011","citation_count":233,"is_preprint":false},{"pmid":"11247302","id":"PMC_11247302","title":"Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2.","date":"2001","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/11247302","citation_count":223,"is_preprint":false},{"pmid":"8895516","id":"PMC_8895516","title":"A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8895516","citation_count":199,"is_preprint":false},{"pmid":"12952931","id":"PMC_12952931","title":"Differential requirements for AP-2 in clathrin-mediated endocytosis.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12952931","citation_count":161,"is_preprint":false},{"pmid":"19776388","id":"PMC_19776388","title":"Critical function of AP-2 gamma/TCFAP2C in mouse embryonic germ cell maintenance.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19776388","citation_count":161,"is_preprint":false},{"pmid":"9811866","id":"PMC_9811866","title":"AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9811866","citation_count":149,"is_preprint":false},{"pmid":"16459302","id":"PMC_16459302","title":"Stonin 2 is an AP-2-dependent endocytic sorting adaptor for synaptotagmin internalization and recycling.","date":"2006","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/16459302","citation_count":137,"is_preprint":false},{"pmid":"14985255","id":"PMC_14985255","title":"Neural crest survival and differentiation in zebrafish depends on mont blanc/tfap2a gene function.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14985255","citation_count":133,"is_preprint":false},{"pmid":"20485680","id":"PMC_20485680","title":"Roles of AP-2 in clathrin-mediated endocytosis.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20485680","citation_count":124,"is_preprint":false},{"pmid":"17258188","id":"PMC_17258188","title":"Redundant activities of Tfap2a and Tfap2c are required for neural crest induction and development of other non-neural ectoderm derivatives in zebrafish embryos.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17258188","citation_count":121,"is_preprint":false},{"pmid":"16227583","id":"PMC_16227583","title":"Clathrin adaptor AP-2 is essential for early embryonal development.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16227583","citation_count":120,"is_preprint":false},{"pmid":"31534499","id":"PMC_31534499","title":"The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31534499","citation_count":96,"is_preprint":false},{"pmid":"17724731","id":"PMC_17724731","title":"Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution.","date":"2007","source":"Journal of experimental zoology. Part B, Molecular and developmental evolution","url":"https://pubmed.ncbi.nlm.nih.gov/17724731","citation_count":93,"is_preprint":false},{"pmid":"10428863","id":"PMC_10428863","title":"AP180 and AP-2 interact directly in a complex that cooperatively assembles clathrin.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428863","citation_count":93,"is_preprint":false},{"pmid":"11310795","id":"PMC_11310795","title":"Gene regulation in melanoma progression by the AP-2 transcription factor.","date":"2001","source":"Pigment cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11310795","citation_count":91,"is_preprint":false},{"pmid":"11969261","id":"PMC_11969261","title":"Transcription factor AP-2 is an essential and direct regulator of epidermal development in Xenopus.","date":"2002","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11969261","citation_count":88,"is_preprint":false},{"pmid":"28619886","id":"PMC_28619886","title":"Tubular clathrin/AP-2 lattices pinch collagen fibers to support 3D cell migration.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28619886","citation_count":86,"is_preprint":false},{"pmid":"15802264","id":"PMC_15802264","title":"The small G-protein Arf6GTP recruits the AP-2 adaptor complex to membranes.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15802264","citation_count":86,"is_preprint":false},{"pmid":"31848212","id":"PMC_31848212","title":"Heterodimerization of TFAP2 pioneer factors drives epigenomic remodeling during neural crest specification.","date":"2019","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/31848212","citation_count":85,"is_preprint":false},{"pmid":"17035630","id":"PMC_17035630","title":"Functional analysis of AP-2 alpha and mu2 subunits.","date":"2006","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17035630","citation_count":79,"is_preprint":false},{"pmid":"23667173","id":"PMC_23667173","title":"miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23667173","citation_count":78,"is_preprint":false},{"pmid":"10721491","id":"PMC_10721491","title":"Role of AP-2 in tumor growth and metastasis of human melanoma.","date":"1999","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10721491","citation_count":77,"is_preprint":false},{"pmid":"16449191","id":"PMC_16449191","title":"AP-2alpha: a regulator of EGF receptor signaling and proliferation in skin epidermis.","date":"2006","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16449191","citation_count":74,"is_preprint":false},{"pmid":"12072434","id":"PMC_12072434","title":"Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12072434","citation_count":72,"is_preprint":false},{"pmid":"28249010","id":"PMC_28249010","title":"TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28249010","citation_count":68,"is_preprint":false},{"pmid":"19685247","id":"PMC_19685247","title":"Reduced TFAP2A function causes variable optic fissure closure and retinal defects and sensitizes eye development to mutations in other morphogenetic regulators.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19685247","citation_count":66,"is_preprint":false},{"pmid":"24335623","id":"PMC_24335623","title":"TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1α signaling pathway.","date":"2013","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/24335623","citation_count":65,"is_preprint":false},{"pmid":"18443366","id":"PMC_18443366","title":"AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs.","date":"2008","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18443366","citation_count":65,"is_preprint":false},{"pmid":"30824562","id":"PMC_30824562","title":"The biological characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancers.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30824562","citation_count":60,"is_preprint":false},{"pmid":"10864206","id":"PMC_10864206","title":"Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10864206","citation_count":59,"is_preprint":false},{"pmid":"25966682","id":"PMC_25966682","title":"Tfap2a and 2b act downstream of Ptf1a to promote amacrine cell differentiation during retinogenesis.","date":"2015","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/25966682","citation_count":58,"is_preprint":false},{"pmid":"11278550","id":"PMC_11278550","title":"A family of AP-2 proteins down-regulate manganese superoxide dismutase expression.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278550","citation_count":58,"is_preprint":false},{"pmid":"33824285","id":"PMC_33824285","title":"TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33824285","citation_count":57,"is_preprint":false},{"pmid":"33713277","id":"PMC_33713277","title":"Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway.","date":"2021","source":"Journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/33713277","citation_count":56,"is_preprint":false},{"pmid":"10645007","id":"PMC_10645007","title":"AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10645007","citation_count":54,"is_preprint":false},{"pmid":"20805990","id":"PMC_20805990","title":"CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20805990","citation_count":53,"is_preprint":false},{"pmid":"10224156","id":"PMC_10224156","title":"Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10224156","citation_count":53,"is_preprint":false},{"pmid":"18275040","id":"PMC_18275040","title":"Characterization of TBX20 in human hearts and its regulation by TFAP2.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18275040","citation_count":52,"is_preprint":false},{"pmid":"20150232","id":"PMC_20150232","title":"AP-2alpha knockout mice exhibit optic cup patterning defects and failure of optic stalk morphogenesis.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20150232","citation_count":52,"is_preprint":false},{"pmid":"14699580","id":"PMC_14699580","title":"Skeletal and pigment cell defects in the lockjaw mutant reveal multiple roles for zebrafish tfap2a in neural crest development.","date":"2004","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/14699580","citation_count":52,"is_preprint":false},{"pmid":"12711551","id":"PMC_12711551","title":"Expression of Tfap2d, the gene encoding the transcription factor Ap-2 delta, during mouse embryogenesis.","date":"2003","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12711551","citation_count":51,"is_preprint":false},{"pmid":"15196531","id":"PMC_15196531","title":"Expression of HER2 and its association with AP-2 in breast cancer.","date":"2004","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/15196531","citation_count":50,"is_preprint":false},{"pmid":"32323475","id":"PMC_32323475","title":"AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32323475","citation_count":46,"is_preprint":false},{"pmid":"32432738","id":"PMC_32432738","title":"TFAP2A is a novel regulator that modulates ferroptosis in gallbladder carcinoma cells via the Nrf2 signalling axis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32432738","citation_count":46,"is_preprint":false},{"pmid":"9712692","id":"PMC_9712692","title":"Redox modulation of AP-2 DNA binding activity in vitro.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9712692","citation_count":46,"is_preprint":false},{"pmid":"22241841","id":"PMC_22241841","title":"Novel Tfap2-mediated control of soxE expression facilitated the evolutionary emergence of the neural crest.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22241841","citation_count":45,"is_preprint":false},{"pmid":"32296015","id":"PMC_32296015","title":"The Ap-2α/Elk-1 axis regulates Sirpα-dependent tumor phagocytosis by tumor-associated macrophages in colorectal cancer.","date":"2020","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32296015","citation_count":45,"is_preprint":false},{"pmid":"16672719","id":"PMC_16672719","title":"Analysis of transcription factor AP-2 expression and function during mouse preimplantation development.","date":"2006","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16672719","citation_count":45,"is_preprint":false},{"pmid":"10648798","id":"PMC_10648798","title":"AP-2 family members regulate basal and cAMP-induced expression of human chorionic gonadotropin.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10648798","citation_count":44,"is_preprint":false},{"pmid":"24732798","id":"PMC_24732798","title":"Suv39h1 mediates AP-2α-dependent inhibition of C/EBPα expression during adipogenesis.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24732798","citation_count":41,"is_preprint":false},{"pmid":"21499258","id":"PMC_21499258","title":"ARFGAP1 promotes AP-2-dependent endocytosis.","date":"2011","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21499258","citation_count":39,"is_preprint":false},{"pmid":"15959839","id":"PMC_15959839","title":"Transcription factor AP-2 and monoaminergic functions in the central nervous system.","date":"2005","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/15959839","citation_count":39,"is_preprint":false},{"pmid":"30256193","id":"PMC_30256193","title":"TFAP2 transcription factors are regulators of lipid droplet biogenesis.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30256193","citation_count":39,"is_preprint":false},{"pmid":"7616204","id":"PMC_7616204","title":"Transcription factor AP-2 regulates expression of the dopamine beta-hydroxylase gene.","date":"1995","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7616204","citation_count":39,"is_preprint":false},{"pmid":"15305293","id":"PMC_15305293","title":"Identification and embryonic expression of a new AP-2 transcription factor, AP-2 epsilon.","date":"2004","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15305293","citation_count":37,"is_preprint":false},{"pmid":"11669459","id":"PMC_11669459","title":"Differential expression of AP-2gamma and AP-2alpha during human trophoblast differentiation.","date":"2001","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11669459","citation_count":36,"is_preprint":false},{"pmid":"11969252","id":"PMC_11969252","title":"Ectopic expression of AP-2alpha transcription factor in the lens disrupts fiber cell differentiation.","date":"2002","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11969252","citation_count":36,"is_preprint":false},{"pmid":"31160420","id":"PMC_31160420","title":"Tfap2a is a novel gatekeeper of nephron differentiation during kidney development.","date":"2019","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31160420","citation_count":36,"is_preprint":false},{"pmid":"32015686","id":"PMC_32015686","title":"TFAP2A Induced ITPKA Serves as an Oncogene and Interacts with DBN1 in Lung Adenocarcinoma.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32015686","citation_count":35,"is_preprint":false},{"pmid":"25781991","id":"PMC_25781991","title":"Tfap2a promotes specification and maturation of neurons in the inner ear through modulation of Bmp, Fgf and notch signaling.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25781991","citation_count":35,"is_preprint":false},{"pmid":"26527400","id":"PMC_26527400","title":"AP-2-complex-mediated endocytosis of Drosophila Crumbs regulates polarity by antagonizing Stardust.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26527400","citation_count":33,"is_preprint":false},{"pmid":"35580127","id":"PMC_35580127","title":"TFAP2 paralogs facilitate chromatin access for MITF at pigmentation and cell proliferation genes.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35580127","citation_count":32,"is_preprint":false},{"pmid":"34210752","id":"PMC_34210752","title":"AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34210752","citation_count":32,"is_preprint":false},{"pmid":"23578821","id":"PMC_23578821","title":"Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23578821","citation_count":32,"is_preprint":false},{"pmid":"28912684","id":"PMC_28912684","title":"Distinct Activities of Tfap2A and Tfap2B in the Specification of GABAergic Interneurons in the Developing Cerebellum.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28912684","citation_count":32,"is_preprint":false},{"pmid":"30689861","id":"PMC_30689861","title":"The TFAP2A-IRF6-GRHL3 genetic pathway is conserved in neurulation.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30689861","citation_count":31,"is_preprint":false},{"pmid":"30768589","id":"PMC_30768589","title":"Long Non-Coding RNA TFAP2A-AS1 Inhibits Cell Proliferation and Invasion in Breast Cancer via miR-933/SMAD2.","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30768589","citation_count":31,"is_preprint":false},{"pmid":"28412966","id":"PMC_28412966","title":"TFAP2A is a component of the ZEB1/2 network that regulates TGFB1-induced epithelial to mesenchymal transition.","date":"2017","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/28412966","citation_count":31,"is_preprint":false},{"pmid":"20808827","id":"PMC_20808827","title":"Expression of human frataxin is regulated by transcription factors SRF and TFAP2.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20808827","citation_count":29,"is_preprint":false},{"pmid":"26780928","id":"PMC_26780928","title":"AP-2α inhibits hepatocellular carcinoma cell growth and migration.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26780928","citation_count":29,"is_preprint":false},{"pmid":"20525283","id":"PMC_20525283","title":"Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes.","date":"2010","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20525283","citation_count":29,"is_preprint":false},{"pmid":"25625848","id":"PMC_25625848","title":"Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.","date":"2014","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25625848","citation_count":29,"is_preprint":false},{"pmid":"36430853","id":"PMC_36430853","title":"Overexpression of Tfap2a in Mouse Oocytes Impaired Spindle and Chromosome Organization.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430853","citation_count":28,"is_preprint":false},{"pmid":"37330579","id":"PMC_37330579","title":"Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37330579","citation_count":28,"is_preprint":false},{"pmid":"29275200","id":"PMC_29275200","title":"Long non-coding RNA CCAL promotes hepatocellular carcinoma progression by regulating AP-2α and Wnt/β-catenin pathway.","date":"2017","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/29275200","citation_count":28,"is_preprint":false},{"pmid":"18620802","id":"PMC_18620802","title":"Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18620802","citation_count":26,"is_preprint":false},{"pmid":"9788434","id":"PMC_9788434","title":"Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9788434","citation_count":26,"is_preprint":false},{"pmid":"16108032","id":"PMC_16108032","title":"Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16108032","citation_count":26,"is_preprint":false},{"pmid":"8885715","id":"PMC_8885715","title":"Craniofacial defects in AP-2 null mutant mice.","date":"1996","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8885715","citation_count":26,"is_preprint":false},{"pmid":"33580997","id":"PMC_33580997","title":"TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation.","date":"2021","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33580997","citation_count":25,"is_preprint":false},{"pmid":"30890602","id":"PMC_30890602","title":"AP-2-Dependent Endocytic Recycling of the Chitin Synthase Chs3 Regulates Polarized Growth in Candida albicans.","date":"2019","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/30890602","citation_count":24,"is_preprint":false},{"pmid":"22886241","id":"PMC_22886241","title":"AP-2α-dependent regulation of Bcl-2/Bax expression affects apoptosis in the trophoblast.","date":"2012","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/22886241","citation_count":22,"is_preprint":false},{"pmid":"10401980","id":"PMC_10401980","title":"Distribution of AP-2 subtypes in the adult mouse brain.","date":"1999","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/10401980","citation_count":22,"is_preprint":false},{"pmid":"38219531","id":"PMC_38219531","title":"Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/38219531","citation_count":21,"is_preprint":false},{"pmid":"32873704","id":"PMC_32873704","title":"Nef homodimers down-regulate SERINC5 by AP-2-mediated endocytosis to promote HIV-1 infectivity.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32873704","citation_count":21,"is_preprint":false},{"pmid":"27888190","id":"PMC_27888190","title":"Tfap2 and Sox1/2/3 cooperatively specify ectodermal fates in ascidian embryos.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27888190","citation_count":20,"is_preprint":false},{"pmid":"33028614","id":"PMC_33028614","title":"Kctd15 regulates nephron segment development by repressing Tfap2a activity.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33028614","citation_count":20,"is_preprint":false},{"pmid":"17695722","id":"PMC_17695722","title":"The AP-2alpha transcription factor regulates tumor cell migration and apoptosis.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17695722","citation_count":20,"is_preprint":false},{"pmid":"21084835","id":"PMC_21084835","title":"Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21084835","citation_count":20,"is_preprint":false},{"pmid":"21375726","id":"PMC_21375726","title":"Alternative TFAP2A isoforms have distinct activities in breast cancer.","date":"2011","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/21375726","citation_count":20,"is_preprint":false},{"pmid":"28439677","id":"PMC_28439677","title":"AP-2α reverses vincristine-induced multidrug resistance of SGC7901 gastric cancer cells by inhibiting the Notch pathway.","date":"2017","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/28439677","citation_count":20,"is_preprint":false},{"pmid":"37586214","id":"PMC_37586214","title":"TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37586214","citation_count":19,"is_preprint":false},{"pmid":"33038379","id":"PMC_33038379","title":"Role of AP-2α/TGF-β1/Smad3 axis in rats with intervertebral disc degeneration.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33038379","citation_count":19,"is_preprint":false},{"pmid":"33753551","id":"PMC_33753551","title":"AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.","date":"2021","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/33753551","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49665,"output_tokens":9380,"usd":0.144847,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19604,"output_tokens":6248,"usd":0.12711,"stage2_stop_reason":"end_turn"},"total_usd":0.271957,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"TFAP2A mRNA is expressed in neural crest cells and their major derivatives (cranial and spinal sensory ganglia, facial mesenchyme) during mouse embryogenesis between E8.5 and E12.5, as determined by RNA in situ hybridization, consistent with a transcriptional regulatory role in peripheral nervous system and craniofacial morphogenesis.\",\n      \"method\": \"RNA in situ hybridization, RNase protection assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by in situ hybridization replicated across multiple time points, but functional consequence not yet established in this paper\",\n      \"pmids\": [\"1989904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted disruption of the mouse AP-2 (Tcfap2a) gene causes perinatal lethality with cranio-abdominoschisis, severe craniofacial dysmorphogenesis, and failure of cranial neural tube closure coinciding with increased apoptosis in the midbrain and first branchial arch; loss of AP-2 does not eliminate expression of twist or Pax-3.\",\n      \"method\": \"Targeted gene disruption (knockout mouse), histology, in situ hybridization\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with defined lethal phenotype, replicated independently in two concurrent papers (PMID 8622765 and related work), multiple morphological readouts\",\n      \"pmids\": [\"8622765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"AP-2alpha and AP-2gamma (but not AP-2beta) bind to and activate the c-erbB-2 (HER2) promoter as homo- or heterodimers, with AP-2alpha and AP-2gamma being 3–4 times more transcriptionally active than AP-2beta at this promoter.\",\n      \"method\": \"DNA binding assays, reporter gene (transient transfection), protein purification/sequencing\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus affinity purification identifying specific family members; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"8895516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"AP-2alpha DNA-binding activity is reversibly inhibited by oxidation of conserved cysteine residues (by diamide or hydrogen peroxide) and restored by reducing agents including thioredoxin, as shown by in vitro DNA-binding and non-reducing immunoblot assays with recombinant human AP-2.\",\n      \"method\": \"In vitro DNA-binding assay (EMSA), non-reducing SDS-PAGE/immunoblot, recombinant protein\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with recombinant protein, single lab, single study\",\n      \"pmids\": [\"9712692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"AP-2 exerts a non-cell-autonomous influence on eye formation and limb patterning (causing major limb duplications) in addition to its cell-autonomous requirements in the neural tube and body wall, as revealed by chimeric mice composed of wild-type and AP-2-null cells.\",\n      \"method\": \"Chimeric mouse analysis (wild-type/AP-2-null)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic chimera approach revealing tissue-level autonomy, single lab but clear functional readouts\",\n      \"pmids\": [\"9811866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"AP-2 directly trans-activates the dopamine beta-hydroxylase (DBH) gene promoter by binding to an AP-2 site at -136 to -115; mutation of this site reduces basal reporter expression 7-fold, and co-transfection of AP-2 expression vector stimulates reporter expression 6-fold.\",\n      \"method\": \"DNase footprinting, reporter gene assay (co-transfection), site-directed mutagenesis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro footprinting plus mutagenesis plus reporter assay in cell culture, single lab\",\n      \"pmids\": [\"7616204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"AP-2 transcription factors (all three members) repress Mn-SOD promoter activity in a DNA-binding-dependent manner; a dominant-negative AP-2 (AP-2B) that cannot bind DNA relieves this repression; AP-2alpha and AP-2gamma are more active repressors than AP-2beta.\",\n      \"method\": \"Reporter gene co-transfection assay, dominant-negative AP-2 expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter plus dominant-negative rescue, single lab, two orthogonal approaches\",\n      \"pmids\": [\"11278550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CITED2 directly interacts with and co-activates all TFAP2 isoforms; TFAP2 transactivation is defective in Cited2-/- embryonic fibroblasts and rescued by ectopic CITED2 expression, establishing CITED2 as a TFAP2 co-activator required for normal neural crest, neural tube, and cardiac development.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay in Cited2-/- fibroblasts, rescue by ectopic expression, knockout mouse phenotype\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction shown by Co-IP, functional rescue in knockout fibroblasts, corroborated by in vivo phenotypic overlap with Tfap2 mutants\",\n      \"pmids\": [\"11694877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TFAP2A interacts with the SUMO-conjugating enzyme UBC9 (identified by two-hybrid screen) via its C-terminal DNA-binding/dimerization domain; endogenous AP-2 is SUMOylated in mammalian cells at conserved lysine 10, and SUMOylation decreases TFAP2A transcriptional activation potential.\",\n      \"method\": \"Yeast two-hybrid screen, in vivo SUMOylation assay, site-directed mutagenesis (K10), reporter gene (transient transfection)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — identified writer (UBC9/SUMO pathway), mapped modification site by mutagenesis, showed functional consequence on transactivation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12072434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"XAP-2 (Xenopus AP-2alpha) is a critical regulator of epidermal determination; ectopic XAP-2 expression restores epidermal gene transcription in neuralized ectoderm, while loss-of-function via antisense oligonucleotides or antimorphic derivatives causes loss of epidermal and gain of neural gene expression, and results in gastrulation failure.\",\n      \"method\": \"Ectopic overexpression in Xenopus embryo, antisense oligonucleotide knockdown, dominant-negative (antimorphic) expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with specific molecular readouts in Xenopus; single lab\",\n      \"pmids\": [\"11969261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In zebrafish, tfap2a (mont blanc/mob) is required for the normal developmental program and survival of neural crest cells in pharyngeal arches 2–7 and trunk; the mutation disrupts the DNA-binding/dimerization domain, abolishes expression of sox9a, wnt5a, dlx2, hoxa2/b2 in craniofacial primordia, and causes apoptosis of a subset of neural crest cells without affecting initial specification or migration.\",\n      \"method\": \"Positional candidate cloning, splice-site mutation characterization, in situ hybridization (neural crest markers), TUNEL/Acridine Orange apoptosis assay, live cell fate tracing\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function allele with defined molecular lesion, multiple downstream target genes assayed, cell fate tracing, replicated with orthogonal apoptosis assays\",\n      \"pmids\": [\"14985255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In zebrafish tfap2a (lockjaw) mutants, defects in hyoid arch cartilage correlate with loss of Hox group 2 gene expression (suggesting homeotic transformation to mandibular fate), and early melanophores fail to develop partly through loss of kit function affecting migration, revealing independent roles for tfap2a in pigment cell specification and Hox-mediated skeletal patterning.\",\n      \"method\": \"Zebrafish mutant analysis, in situ hybridization (Hox genes, pigment markers), genetic interaction with kit\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple molecular marker readouts and pathway placement, single lab\",\n      \"pmids\": [\"14699580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Conditional knockout of AP-2alpha in mouse epidermis causes elevated EGFR expression in differentiating layers, hyperproliferation upon EGF stimulation, and excessive PI3K/Akt activity; chromatin immunoprecipitation and promoter assays identify EGFR as a direct transcriptional target of AP-2alpha repression.\",\n      \"method\": \"Conditional knockout mouse (cre-lox), chromatin immunoprecipitation (ChIP), promoter reporter assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — conditional KO with defined phenotype, ChIP demonstrating direct promoter occupancy, reporter assay confirming repression; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16449191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In zebrafish, tfap2a and tfap2c act redundantly in neural crest induction; simultaneous inhibition of both genes utterly prevents neural crest induction, and cell transplant experiments indicate this role is cell-autonomous.\",\n      \"method\": \"Antisense morpholino knockdown, cell transplantation assay, in situ hybridization\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double knockdown with cell-autonomous transplant evidence, single lab\",\n      \"pmids\": [\"17258188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TFAP2 transcription factors are identified as repressors of the TBX20 gene: functional TFAP2 binding sites were found within the human TBX20 core promoter, and TFAP2 repressed TBX20 expression in vitro (reporter assay) and in vivo (ChIP and cardiac biopsy analysis showing decreased TFAP2C in TOF patients).\",\n      \"method\": \"Reporter gene assay, ChIP, cardiac biopsy expression analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus ChIP plus in vivo correlation, single lab\",\n      \"pmids\": [\"18275040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AP-2alpha (TFAP2A) directly binds to two regions of the CDKN1A (p21cip) promoter—a proximal AP-2 site and an upstream region near the p53 binding site—as shown by ChIP; mutation of the proximal AP-2 site reduces p53-independent p21 expression, and this interaction pattern changes temporally post-induction.\",\n      \"method\": \"ChIP, site-directed mutagenesis of promoter, reporter gene assay\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP with mutagenesis and reporter assay, single lab, multiple approaches\",\n      \"pmids\": [\"21084835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In AP-2alpha knockout mice, loss of AP-2alpha in multiple craniofacial tissues disrupts optic cup patterning and optic stalk morphogenesis; ectopic neural retina replaces RPE, coloboma and optic stalk extension failure occur, associated with increased Sonic Hedgehog signaling and expanded PAX2-positive optic stalk-like tissue in the optic cup.\",\n      \"method\": \"AP-2alpha knockout mouse, in situ hybridization, immunofluorescence, Shh pathway analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with defined molecular pathway (Shh) disturbance; single lab, multiple molecular markers\",\n      \"pmids\": [\"20150232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TFAP2 and SRF bind directly to FXN (frataxin) promoter sequences as shown by ChIP and EMSA; mutagenesis of these binding sites reduces FXN promoter activity; overexpression of TFAP2 increases frataxin mRNA and protein levels in HEK293 and SH-SY5Y cells and in Friedreich ataxia patient lymphoblasts.\",\n      \"method\": \"ChIP, EMSA, luciferase reporter mutagenesis, overexpression in cell lines and patient cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding by ChIP+EMSA plus mutagenesis plus functional rescue, single lab\",\n      \"pmids\": [\"20808827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CREB suppresses AP-2alpha (TFAP2A) expression in metastatic melanoma via a dual mechanism: direct binding of CREB to the AP-2alpha promoter and CREB-induced upregulation of E2F-1, both of which repress AP-2alpha; silencing CREB restores AP-2alpha expression and upregulates p21Waf1 and downregulates MCAM/MUC18.\",\n      \"method\": \"shRNA silencing of CREB, PKA inhibitor treatment, promoter ChIP, rescue expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual mechanisms demonstrated by ChIP and rescue experiments; single lab\",\n      \"pmids\": [\"20805990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tfap2a directly activates sox10 expression in neural crest cells; zebrafish rescue experiments (depleting endogenous tfap2a and replacing with various Tfap2 orthologs) show this regulatory interaction arose with the emergence of the neural crest, as AP2 and SoxE are not co-expressed in amphioxus and neural crest enhancers are absent proximal to amphioxus soxE.\",\n      \"method\": \"Zebrafish rescue with ortholog series, in situ hybridization, enhancer analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct target relationship established by rescue genetics and comparative enhancer analysis; single lab\",\n      \"pmids\": [\"22241841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFAP2A mutations causing Branchio-Oculo-Facial Syndrome (BOFS) localize predominantly to the DNA-binding domain; functional analysis shows that individual mutations reduce DNA binding to different extents, yet all show significantly reduced transcriptional activity; several mutants show altered nuclear:cytoplasmic distribution and can exert dominant-negative activity on wild-type AP-2alpha.\",\n      \"method\": \"Reporter gene assay (transcriptional activity), EMSA (DNA binding), subcellular localization (immunofluorescence), dominant-negative assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple BOFS mutants analyzed by three orthogonal functional methods (DNA binding, transactivation, localization) in a single systematic study\",\n      \"pmids\": [\"23578821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AP-2alpha recruits the histone H3K9 methyltransferases Suv39h1 and G9a to the C/EBPalpha promoter; G9a deposits H3K9me2 (substrate for Suv39h1) and Suv39h1 deposits H3K9me3, together mediating AP-2alpha-dependent transcriptional repression of C/EBPalpha to inhibit adipogenesis.\",\n      \"method\": \"Co-immunoprecipitation (AP-2alpha with Suv39h1 and G9a), ChIP (H3K9me2/me3 at C/EBPalpha promoter), knockdown/overexpression in 3T3-L1 preadipocytes\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP plus ChIP for histone marks plus functional rescue; mechanistic pathway reconstituted with multiple orthogonal methods in one study\",\n      \"pmids\": [\"24732798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tfap2a and Tfap2b act downstream of Ptf1a to promote amacrine cell differentiation in the mouse retina; RNA-seq shows Tfap2a/b expression is dramatically reduced in Ptf1a-null retinas; overexpression promotes glycinergic/GABAergic amacrine cells at the expense of photoreceptors, and simultaneous knockdown has the opposite effect, placing Tfap2a/b in the Foxn4/RORβ1–Ptf1a–Tfap2a/b cascade.\",\n      \"method\": \"RNA-seq, immunolabeling, overexpression, simultaneous knockdown (siRNA/shRNA), retinal explant analysis\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by gain- and loss-of-function with molecular marker readouts; single lab\",\n      \"pmids\": [\"25966682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In zebrafish inner ear, Tfap2a coordinates BMP7a, Fgf, and Notch signaling to regulate statoacoustic ganglion (SAG) neurogenesis; Tfap2a acts non-cell-autonomously to activate Bmp7a expression, which in turn inhibits both Fgf and Notch; blocking Bmp signaling reverses the effects of Tfap2a overexpression.\",\n      \"method\": \"Loss-of-function/gain-of-function in zebrafish, genetic mosaic analysis, pharmacological inhibitors, in situ hybridization\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement by epistasis and genetic mosaic, multiple signaling readouts; single lab\",\n      \"pmids\": [\"25781991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TFAP2A paralogs (TFAP2A and TFAP2B) in mouse neural crest are required for induction of the melanocyte lineage; Wnt1-Cre deletion of both Tfap2a and Tfap2b almost completely eliminates melanocytes but retains sensory ganglia; ChIP-seq shows TFAP2A co-occupies regulatory elements with MITF at pigmentation genes (e.g., TRPM1 promoter), and deletion of TFAP2A binding sites abolishes TRPM1 promoter activity.\",\n      \"method\": \"Conditional double knockout (Wnt1-Cre), ChIP-seq, luciferase reporter with site deletion, zebrafish genetic interaction\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP-seq plus mutagenesis plus conditional double KO plus genetic interaction; multiple labs and organisms\",\n      \"pmids\": [\"28249010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TFAP2A functions as a repressor of ZEB2 by directly binding the ZEB2 promoter, as demonstrated by EMSA and ChIP in NMuMG cells undergoing EMT; TFAP2A is a component of the core EMT gene regulatory network.\",\n      \"method\": \"EMSA, ChIP, overexpression and endogenous knockdown analysis in NMuMG EMT model\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding demonstrated by EMSA and ChIP with functional consequence on ZEB2; single lab\",\n      \"pmids\": [\"28412966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2 family members mediate Wnt3a-induced lipid droplet biogenesis; TFAP2 knockdown prevents Wnt-induced lipid droplet formation, identifying TFAP2 transcription factors as regulators of lipid droplet biogenesis downstream of Wnt signaling and independent of canonical TCF/LEF factors.\",\n      \"method\": \"RNAi knockdown, lipid droplet quantification (imaging), reporter assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific lipid droplet readout and pathway placement; single lab\",\n      \"pmids\": [\"30256193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFAP2A acts as a pioneer factor that activates distinct sets of genomic regions at different stages of neural crest development; TFAP2A/C heterodimers activate neural plate border induction programs during gastrula stages, while TFAP2A/B heterodimers reorganize the epigenomic landscape during neurulation to promote neural crest specification, representing a stage-specific molecular switch.\",\n      \"method\": \"ChIP-seq (genomic occupancy), ATAC-seq (chromatin accessibility), in vivo Xenopus model, dimerization partner analysis\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — pioneer factor activity shown by ChIP-seq and chromatin accessibility assays with partner-specific functional analysis; single lab but multiple orthogonal genomic methods\",\n      \"pmids\": [\"31848212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the zebrafish pronephros, tfap2a acts downstream of irx3b (a distal lineage transcription factor) to activate a gene regulatory circuit comprising tfap2b, irx1a, and solute transporter genes (slc12a1, kcnj1a.1, stc1) that dictate distal nephron segment identity; kctd15a/b repress Tfap2a activity, and tfap2a reciprocally promotes kctd15a/b transcription, forming an autoregulatory feedback circuit.\",\n      \"method\": \"Forward genetic screen (zebrafish), morpholino knockdown, overexpression, in situ hybridization, epistasis analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by genetic screen and multiple rescue/knockdown combinations; single lab\",\n      \"pmids\": [\"31160420\", \"33028614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AP-2alpha directly binds the Nanog gene regulatory region (shown by EMSA and luciferase reporter assay) and reduces Nanog, Sox2, and CD133 expression; AP-2alpha also indirectly downregulates Nanog by inhibiting the IL6/JAK2/STAT3 signaling pathway, thereby reducing MGMT and PD-L1 expression and suppressing glioma stem cell self-renewal.\",\n      \"method\": \"Luciferase reporter assay, EMSA, Western blot, sphere-formation assay, xenograft model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA binding by EMSA plus reporter assay plus pathway inhibition phenotype; single lab\",\n      \"pmids\": [\"31534499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Over-expression of the Tfap2a-Irf6-Grhl3 genetic pathway is conserved in neurulation: over-expression of Irf6 causes exencephaly by suppressing Tfap2a and Grhl3 expression, while loss of Irf6 reduces Tfap2a and Grhl3 in tail tissues; Tfap2a and Grhl3 are thus epistatic to Irf6 in this pathway controlling both neural tube closure and orofacial development.\",\n      \"method\": \"Mouse overexpression and loss-of-function models, in situ hybridization, sequencing of human neural tube defect samples\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in mouse established by gain- and loss-of-function with molecular marker readouts; single lab\",\n      \"pmids\": [\"30689861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In melanoma, AP-2alpha (TFAP2A) drives metastasis by transcriptionally activating EZH2 and other E2F pathway genes; BioID screen reveals AP-2alpha interacts with members of the NuRD complex; loss of AP-2alpha removes activating chromatin marks from EZH2 and E2F target gene promoters through NuRD-mediated repression; tazemetostat (EZH2 inhibitor) efficacy is AP-2alpha-dependent.\",\n      \"method\": \"BioID proximity labeling screen, ChIP (histone marks), CRISPR/shRNA knockout, drug sensitivity assay, single-cell RNA-seq\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BioID identifies NuRD complex interaction, ChIP shows chromatin mark changes; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34210752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AP-2alpha (TFAP2A) binds directly to the CD274 (PD-L1) promoter and inhibits its transcriptional activity; AP-2alpha also enhances endocytosis and degradation of PD-L1 protein; AP-2alpha gene is epigenetically silenced in glioma by an EZH2/H3K27Me3/DNMT1 complex-mediated methylation mechanism.\",\n      \"method\": \"Reporter gene assay, ChIP (AP-2alpha on CD274 promoter), flow cytometry (PD-L1 surface levels), endocytosis assay, bisulfite sequencing/ChIP for H3K27me3/DNMT1\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by ChIP plus reporter plus endocytosis assay; single lab, multiple mechanisms tested\",\n      \"pmids\": [\"37330579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AP-2alpha (TFAP2A) drives cell cycle S-phase progression in colon cancer through transcriptional activation of TGM2, which in turn activates AKT phosphorylation; CRISPR/shRNA knockout of TFAP2A delays S-phase to G2-M progression and decreases pAKT, mediated through TGM2; loss of AP-2alpha also induces resistance to PI3K inhibitor buparlisib.\",\n      \"method\": \"CRISPR-Cas9 and shRNA knockout, ChIP-seq, RNA-seq, FACS cell cycle analysis, Premo FUCCI cell cycle reporter, AKT phosphorylation assay, xenograft\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP-seq identifying direct target TGM2, functional cell cycle and signaling readouts with CRISPR KO and multiple orthogonal methods in one systematic study\",\n      \"pmids\": [\"33753551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFAP2 paralogs (TFAP2A and TFAP2C) are required for MITF binding and chromatin accessibility at pigmentation and proliferation gene enhancers in melanoma cells; TFAP2-KO (CRISPR) cells show reduced H3K27Ac and MITF binding at co-occupied enhancers, decreased proliferation, and increased cell adhesion; TFAP2 and MITF co-operatively activate a subset of enhancers with TFAP2 acting upstream to facilitate MITF access.\",\n      \"method\": \"CRISPR knockout, ATAC-seq, ChIP-seq (TFAP2A, MITF, H3K27Ac, H3K27Me3), RNA-seq\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple genome-wide orthogonal assays in CRISPR KO cells; rigorous integrated analysis; single lab but comprehensive multi-omic approach\",\n      \"pmids\": [\"35580127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Alternative TFAP2A isoforms differ in transcriptional activity: isoforms 1a, 1b, and 1c share a transactivation mechanism recruiting CITED2/4 adaptor proteins and the p300/CBP co-activators, but isoform 1b and 1c are stronger activators of the ERBB2 promoter; only isoform 1a can repress transcription, and this repressor activity requires an intact sumoylation motif in its unique N-terminus.\",\n      \"method\": \"Reporter gene assay, isoform-specific antibody characterization, isoform expression in breast cell lines and tumors\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays with multiple isoforms plus sumoylation motif requirement established; single lab\",\n      \"pmids\": [\"21375726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SRC-mediated tyrosine phosphorylation of YAP1 facilitates YAP1 interaction with TFAP2A, forming a YAP1/TEAD-TFAP2A (YTT) complex that co-occupies regulatory regions of trastuzumab resistance genes (EGFR, HER2, H19, CTGF) and drives their transcription; disruption of the YTT complex or SRC inhibition sensitizes HER2+ breast cancer cells to trastuzumab.\",\n      \"method\": \"Co-IP (YAP1-TFAP2A interaction), ChIP-seq (YTT complex occupancy), reporter gene assay, SRC inhibition, drug sensitivity assay in vitro and in vivo\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP-seq plus functional drug sensitivity; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38219531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lactate from CRC cells induces nuclear translocation of Ap-2alpha in tumor-associated macrophages (TAMs), where it functions as a transcriptional activator of Elk-1 by binding the conserved element GCCTGC at -1396/-1391 in the mouse Elk-1 promoter; Elk-1 then binds the Sirpα promoter to upregulate Sirpα and suppress TAM phagocytosis.\",\n      \"method\": \"Reporter gene assay, EMSA/ChIP (Ap-2alpha binding to Elk-1 promoter), macrophage-specific knockout mouse, nuclear translocation assay\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA binding by EMSA and reporter assay, macrophage-specific KO with phagocytosis readout; single lab\",\n      \"pmids\": [\"32296015\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFAP2A (AP-2alpha) is a sequence-specific transcription factor that functions as both a transcriptional activator and repressor, forming homo- and heterodimers with paralogous TFAP2 family members via its C-terminal helix-span-helix dimerization domain; it acts as a pioneer factor to remodel chromatin at neural crest and melanocyte enhancers (facilitating MITF binding), recruits co-activators CITED2/p300/CBP to activate targets (e.g., DBH, frataxin, ERBB2, CDKN1A) and co-repressors Suv39h1/G9a to deposit H3K9me3 and silence genes (e.g., C/EBPalpha, EGFR, ZEB2, Mn-SOD); its DNA-binding activity is regulated by redox state (cysteine oxidation) and by SUMOylation at lysine 10 (reducing transactivation); TFAP2A is epigenetically silenced in melanoma by CREB/E2F-1-mediated promoter repression and by DNMT1/EZH2-driven CpG methylation; and it controls cell cycle S-phase progression through TGM2-mediated AKT activation, melanocyte lineage induction, neural crest survival and differentiation, and multiple organ morphogenesis (craniofacial, renal, ocular).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TFAP2A (AP-2alpha) is a sequence-specific transcription factor that orchestrates neural crest development, craniofacial and organ morphogenesis, and lineage specification, with both activator and repressor functions [#1, #10, #24]. It is expressed in neural crest cells and their derivatives during embryogenesis [#0], and its loss causes failure of cranial neural tube closure, craniofacial dysmorphogenesis, and increased neural crest apoptosis in mouse and zebrafish [#1, #10]. Mechanistically, TFAP2A acts as a pioneer factor that remodels chromatin in a partner-specific manner: TFAP2A/C heterodimers drive neural plate border induction while TFAP2A/B heterodimers reorganize the epigenome for neural crest specification [#27], and in melanocytes it (with TFAP2C) opens enhancers to facilitate MITF binding and co-operatively activate pigmentation genes such as TRPM1 [#24, #34]. As an activator it binds and trans-activates target promoters including DBH, FXN (frataxin), and ERBB2, recruiting the CITED2 adaptor and p300/CBP co-activators [#5, #7, #17, #35]; as a repressor it recruits the H3K9 methyltransferases Suv39h1 and G9a to deposit H3K9me2/me3 and silence targets such as C/EBPalpha, and directly represses EGFR, ZEB2, and Mn-SOD [#21, #12, #25, #6]. Its DNA-binding activity is redox-regulated through oxidation of conserved cysteines [#3], and SUMOylation at lysine 10 via UBC9 reduces its transactivation potential [#8]. In cancer, TFAP2A controls cell cycle S-phase progression through transcriptional activation of TGM2 and downstream AKT signaling [#33], is epigenetically silenced in melanoma and glioma by CREB/E2F-1 and EZH2/DNMT1-mediated mechanisms [#18, #32], and partners with NuRD and YAP1/TEAD complexes to regulate target gene chromatin states [#31, #36]. Human TFAP2A mutations, predominantly in the DNA-binding domain, cause Branchio-Oculo-Facial Syndrome, reducing transactivation and conferring dominant-negative activity [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established where TFAP2A is deployed in the embryo, anchoring the hypothesis that it regulates neural crest and craniofacial programs.\",\n      \"evidence\": \"RNA in situ hybridization and RNase protection across mouse embryonic stages E8.5–E12.5\",\n      \"pmids\": [\"1989904\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Expression alone does not establish function\", \"No direct target genes identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that TFAP2A is essential for neural tube closure and craniofacial development, converting an expression correlation into a causal developmental requirement.\",\n      \"evidence\": \"Targeted gene disruption in mouse with histology and in situ hybridization\",\n      \"pmids\": [\"8622765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets driving the phenotype not defined\", \"Cell-autonomy not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified the first direct activation target and DNA-binding mechanism, showing TFAP2A trans-activates promoters through defined AP-2 sites.\",\n      \"evidence\": \"DNase footprinting, site-directed mutagenesis, and reporter assays on the DBH promoter; reporter/affinity work on c-erbB-2\",\n      \"pmids\": [\"7616204\", \"8895516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-activator requirements not yet defined\", \"In vivo relevance of these targets untested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Revealed that TFAP2A activity is post-translationally controlled, with DNA binding reversibly inhibited by cysteine oxidation, linking its function to cellular redox state.\",\n      \"evidence\": \"In vitro EMSA and non-reducing immunoblot with recombinant protein and oxidizing/reducing agents\",\n      \"pmids\": [\"9712692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro reconstitution only\", \"Physiological relevance of redox regulation in vivo unestablished\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Distinguished cell-autonomous from non-cell-autonomous requirements, showing TFAP2A influences eye and limb patterning at the tissue level beyond its own lineage.\",\n      \"evidence\": \"Chimeric mouse analysis combining wild-type and AP-2-null cells\",\n      \"pmids\": [\"9811866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling intermediaries mediating non-autonomous effects unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified CITED2 as a required co-activator, providing the first molecular partner explaining how TFAP2A activates transcription during development.\",\n      \"evidence\": \"Co-IP, reporter rescue in Cited2-/- fibroblasts, and knockout mouse phenotype overlap\",\n      \"pmids\": [\"11694877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct contact with general co-activators not mapped here\", \"Target-specific recruitment unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined SUMOylation at lysine 10 via UBC9 as a negative regulator of TFAP2A transactivation, establishing a covalent switch on its activity.\",\n      \"evidence\": \"Yeast two-hybrid, in vivo SUMOylation assay, K10 mutagenesis, reporter assays\",\n      \"pmids\": [\"12072434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO E3 ligase not identified\", \"Genomic targets affected by SUMOylation undefined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established a conserved developmental fate-decision role, with AP-2alpha required for epidermal versus neural ectoderm choice.\",\n      \"evidence\": \"Gain- and loss-of-function in Xenopus with epidermal/neural gene readouts\",\n      \"pmids\": [\"11969261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct targets in epidermal determination not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pinpointed the neural crest survival and craniofacial patterning role to the DNA-binding/dimerization domain and a downstream target network (sox9a, dlx2, hoxa2/b2), separating differentiation from specification and migration.\",\n      \"evidence\": \"Zebrafish positional cloning, marker in situ hybridization, apoptosis assays, and cell fate tracing in mont blanc/lockjaw mutants\",\n      \"pmids\": [\"14985255\", \"14699580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which targets are direct vs indirect not fully resolved\", \"Mechanism of cell-type-specific apoptosis unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined TFAP2A as a direct transcriptional repressor in differentiated tissue, restraining EGFR and downstream PI3K/Akt signaling in epidermis.\",\n      \"evidence\": \"Conditional epidermal knockout, ChIP, and promoter reporter assays\",\n      \"pmids\": [\"16449191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor machinery at EGFR not identified in this study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Expanded the direct target repertoire across activation (FXN) and repression (Mn-SOD, CDKN1A, TBX20), establishing TFAP2A as a bifunctional regulator engaging promoters context-dependently.\",\n      \"evidence\": \"ChIP, EMSA, promoter mutagenesis, reporter assays, and overexpression across cell and patient models\",\n      \"pmids\": [\"20808827\", \"11278550\", \"21084835\", \"18275040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of activator vs repressor mode at a given promoter unclear\", \"Co-factors mediating each mode not defined here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed TFAP2A is epigenetically silenced in melanoma via CREB/E2F-1, linking its loss to metastatic gene programs and p21/MCAM regulation.\",\n      \"evidence\": \"shRNA silencing of CREB, PKA inhibition, promoter ChIP, and rescue in melanoma cells\",\n      \"pmids\": [\"20805990\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CREB-driven silencing initiates or maintains melanoma progression untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established TFAP2A as a direct upstream activator of sox10 and traced the origin of this regulatory link to the evolutionary emergence of the neural crest.\",\n      \"evidence\": \"Zebrafish rescue with ortholog series, in situ hybridization, comparative enhancer analysis\",\n      \"pmids\": [\"22241841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enhancer contacts in vertebrates not mapped at base-pair resolution\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reconstituted the repressive chromatin mechanism, showing TFAP2A recruits G9a and Suv39h1 to deposit H3K9me2/me3 and silence target genes such as C/EBPalpha.\",\n      \"evidence\": \"Co-IP, ChIP for H3K9me2/me3, and knockdown/overexpression in 3T3-L1 preadipocytes\",\n      \"pmids\": [\"24732798\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this complex operates at other repressed targets not tested here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed TFAP2A in defined transcriptional cascades for retinal amacrine cell fate and inner ear neurogenesis, showing it integrates signaling pathways during organ development.\",\n      \"evidence\": \"RNA-seq, epistasis, gain/loss-of-function in mouse retina and zebrafish inner ear with genetic mosaics and inhibitors\",\n      \"pmids\": [\"25966682\", \"25781991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect targets within these cascades not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined TFAP2A (with TFAP2B) as the inducer of the melanocyte lineage and demonstrated genomic co-occupancy with MITF at pigmentation enhancers.\",\n      \"evidence\": \"Conditional double knockout (Wnt1-Cre), ChIP-seq, reporter site-deletion, and zebrafish genetic interaction\",\n      \"pmids\": [\"28249010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of MITF facilitation not yet defined at chromatin level in this study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Added ZEB2 to the directly repressed targets, positioning TFAP2A within the core EMT gene regulatory network.\",\n      \"evidence\": \"EMSA and ChIP with knockdown/overexpression in the NMuMG EMT model\",\n      \"pmids\": [\"28412966\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single EMT model; broader EMT relevance untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established TFAP2A as a stage-specific pioneer factor, with distinct heterodimer partners directing chromatin opening at successive neural crest developmental programs.\",\n      \"evidence\": \"ChIP-seq and ATAC-seq with partner-specific analysis in Xenopus\",\n      \"pmids\": [\"31848212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of partner-dependent pioneering not resolved\", \"How the A/C-to-A/B switch is timed unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Embedded TFAP2A in tissue-specific genetic circuits, including a distal nephron autoregulatory loop with kctd15a/b and an Irf6-Tfap2a-Grhl3 neurulation/orofacial pathway.\",\n      \"evidence\": \"Forward genetic screen, knockdown/overexpression, epistasis in zebrafish pronephros and mouse models\",\n      \"pmids\": [\"31160420\", \"30689861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct targets within each circuit incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed context-dependent oncogenic roles, with TFAP2A activating EZH2/E2F programs via NuRD interaction and driving S-phase progression through TGM2/AKT.\",\n      \"evidence\": \"BioID proximity labeling, ChIP, CRISPR/shRNA knockout, ChIP-seq, FACS cell cycle and drug sensitivity assays in melanoma and colon cancer\",\n      \"pmids\": [\"34210752\", \"33753551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TFAP2A switches between NuRD-repressive and activating outputs unclear\", \"Direct vs indirect EZH2/E2F regulation not fully separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended TFAP2A function to immune modulation and protein-level regulation, repressing CD274/PD-L1 transcription, promoting its endocytosis, and activating Elk-1 in lactate-stimulated tumor-associated macrophages.\",\n      \"evidence\": \"Reporter assays, ChIP/EMSA, flow cytometry, endocytosis assays, and macrophage-specific knockout mice\",\n      \"pmids\": [\"37330579\", \"32296015\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking nuclear translocation signal to PD-L1 protein trafficking unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected TFAP2A directly to human disease, showing Branchio-Oculo-Facial Syndrome mutations cluster in the DNA-binding domain and impair transactivation while exerting dominant-negative effects.\",\n      \"evidence\": \"Systematic functional analysis of BOFS mutants by EMSA, reporter assays, and subcellular localization\",\n      \"pmids\": [\"23578821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation for variable BOFS features not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a YAP1/TEAD-TFAP2A complex assembled by SRC-mediated YAP1 phosphorylation that drives trastuzumab-resistance genes, defining a druggable TFAP2A-containing complex.\",\n      \"evidence\": \"Co-IP, ChIP-seq, reporter assays, SRC inhibition, and drug sensitivity in HER2+ breast cancer models\",\n      \"pmids\": [\"38219531\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural details of the YTT complex not resolved\", \"Generalizability beyond HER2+ breast cancer untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what molecular determinants dictate TFAP2A's switch between activator and repressor modes at a given locus, and how dimer-partner choice, SUMOylation, redox state, and co-factor recruitment are integrated to control its pioneer and lineage-specifying functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking post-translational state to activator/repressor choice\", \"Structural basis of partner-specific pioneering unknown\", \"Hierarchy among co-activator (CITED2/p300) and co-repressor (G9a/Suv39h1/NuRD) recruitment unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 6, 12, 21, 24, 25, 27, 33]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 5, 15, 17, 20, 25, 29]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20, 37]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [27, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 12, 21, 24, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 10, 24, 27]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [21, 27, 34]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [15, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 31, 33]}\n    ],\n    \"complexes\": [\"NuRD complex (interactor)\", \"YAP1/TEAD-TFAP2A (YTT) complex\"],\n    \"partners\": [\"TFAP2C\", \"TFAP2B\", \"CITED2\", \"UBC9\", \"SUV39H1\", \"G9a (EHMT2)\", \"MITF\", \"YAP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}